These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 7912423)
21. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Laframboise S; Chapman W; McLaughlin J; Andrulis IL Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169 [TBL] [Abstract][Full Text] [Related]
22. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer. Malone JP; Stephens JA; Grecula JC; Rhoades CA; Ghaheri BA; Schuller DE Head Neck; 2004 Jul; 26(7):561-72. PubMed ID: 15229898 [TBL] [Abstract][Full Text] [Related]
23. Carcinosarcoma of the ovary-a case series. Rutledge TL; Gold MA; McMeekin DS; Huh WK; Powell MA; Lewin SN; Mutch DG; Johnson GA; Walker JL; Mannel RS Gynecol Oncol; 2006 Jan; 100(1):128-32. PubMed ID: 16213011 [TBL] [Abstract][Full Text] [Related]
24. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma]. Zhao XD; Zhang Q; Zhang Y Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882 [TBL] [Abstract][Full Text] [Related]
25. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy. Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812 [TBL] [Abstract][Full Text] [Related]
26. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409 [TBL] [Abstract][Full Text] [Related]
27. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A; Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910 [TBL] [Abstract][Full Text] [Related]
28. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results. Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971 [TBL] [Abstract][Full Text] [Related]
29. Recent advances in the management of women with ovarian cancer. Eltabbakh GH Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412 [TBL] [Abstract][Full Text] [Related]
30. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318 [TBL] [Abstract][Full Text] [Related]
31. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Mayerhofer K; Kucera E; Zeisler H; Speiser P; Reinthaller A; Sevelda P Gynecol Oncol; 1997 Jan; 64(1):109-13. PubMed ID: 8995557 [TBL] [Abstract][Full Text] [Related]
32. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370 [TBL] [Abstract][Full Text] [Related]
34. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist]. Sugiyama T; Yoshizaki A; Hatayama S Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537 [TBL] [Abstract][Full Text] [Related]
36. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547 [TBL] [Abstract][Full Text] [Related]
37. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864 [TBL] [Abstract][Full Text] [Related]
38. Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer. Fanning J; Colgrove M; Phibbs G Gynecol Oncol; 2000 Oct; 79(1):97-100. PubMed ID: 11006039 [TBL] [Abstract][Full Text] [Related]